Human trials recently began to use the genome editing technology CRISPR to treat sickle cell anemia using edited stem cells. Sickle cell anemia is caused by a single DNA Mutation, and is also a disorder of the red blood cell. Given that this is a more simplistic genetic issue to address (i.e. there is only one DNA mutation to correct), and that the disorder affects an easily replaceable connective tissue, is the application of CRISPR limited as a treatment? Could CRISPR be used to treat disorders that are a results of multiple DNA mutation, and that affect a different types of tissue?